Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.
Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Aihara Y, Nishimura N, Takeda K, Okura Y, Kawaratani H, Fukui H. Douhara A, et al. Among authors: okura y. Mol Med Rep. 2015 Mar;11(3):1693-700. doi: 10.3892/mmr.2014.2995. Epub 2014 Nov 24. Mol Med Rep. 2015. PMID: 25421042 Free PMC article.
Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis.
Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H. Namisaki T, et al. Among authors: okura y. J Gastroenterol. 2016 Feb;51(2):162-72. doi: 10.1007/s00535-015-1104-x. Epub 2015 Jul 21. J Gastroenterol. 2016. PMID: 26190501
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Nishimura N, Kitade M, Noguchi R, Namisaki T, Moriya K, Takeda K, Okura Y, Aihara Y, Douhara A, Kawaratani H, Asada K, Yoshiji H. Nishimura N, et al. Among authors: okura y. J Gastroenterol. 2016 Dec;51(12):1141-1149. doi: 10.1007/s00535-016-1200-6. Epub 2016 Mar 29. J Gastroenterol. 2016. PMID: 27025708
Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model.
Seki K, Kitade M, Nishimura N, Kaji K, Asada K, Namisaki T, Moriya K, Kawaratani H, Okura Y, Takaya H, Sawada Y, Sato S, Nakanishi K, Yoshiji H. Seki K, et al. Among authors: okura y. Oncotarget. 2018 Jun 19;9(47):28638-28651. doi: 10.18632/oncotarget.25587. eCollection 2018 Jun 19. Oncotarget. 2018. PMID: 29983886 Free PMC article.
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis.
Namisaki T, Kaji K, Shimozato N, Kaya D, Ozutsumi T, Tsuji Y, Fujinaga Y, Kitagawa K, Furukawa M, Sato S, Sawada Y, Nishimura N, Takaya H, Okura Y, Seki K, Kawaratani H, Moriya K, Noguchi R, Asada K, Akahane T, Mitoro A, Yoshiji H. Namisaki T, et al. Among authors: okura y. Indian J Gastroenterol. 2022 Apr;41(2):169-180. doi: 10.1007/s12664-021-01220-5. Epub 2022 Mar 12. Indian J Gastroenterol. 2022. PMID: 35279807
Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes.
Mashitani T, Noguchi R, Okura Y, Namisaki T, Mitoro A, Ishii H, Nakatani T, Kikuchi E, Moriyasu H, Matsumoto M, Sato S, An T, Morita H, Aizawa S, Tokuoka Y, Ishikawa M, Matsumura Y, Ohira H, Kogure A, Noguchi K, Yoshiji H. Mashitani T, et al. Among authors: okura y. Biomed Rep. 2016 Feb;4(2):183-187. doi: 10.3892/br.2016.569. Epub 2016 Jan 7. Biomed Rep. 2016. PMID: 26893835 Free PMC article.
Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis.
Namisaki T, Moriya K, Noguchi R, Kitade M, Kawaratani H, Yamao J, Mitoro A, Yoshida M, Sawai M, Uejima M, Mashitani T, Takeda K, Okura Y, Kaji K, Takaya H, Aihara Y, Douhara A, Nishimura N, Sawada Y, Sato S, Seki K, Yoshiji H. Namisaki T, et al. Among authors: okura y. Hepatol Res. 2017 Mar;47(3):E178-E186. doi: 10.1111/hepr.12746. Epub 2016 Jul 21. Hepatol Res. 2017. PMID: 27189879 No abstract available.
Predictive parameter of tolvaptan effectiveness in cirrhotic ascites.
Kawaratani H, Fukui H, Moriya K, Noguchi R, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K, Nishimura N, Takaya H, Aihara Y, Sawada Y, Sato S, Seki K, Mitoro A, Yamao J, Yoshiji H. Kawaratani H, et al. Among authors: okura y. Hepatol Res. 2017 Aug;47(9):854-861. doi: 10.1111/hepr.12826. Epub 2016 Nov 9. Hepatol Res. 2017. PMID: 27704665
290 results